<DOC>
	<DOC>NCT02517320</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of MT-3995 in subjects with diabetic nephropathy, compared with placebo, using urine albumin- to-creatinine ratio (UACR) in the first morning void urine sample as an indicator.</brief_summary>
	<brief_title>Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Type 2 diabetes mellitus Glycated hemoglobin(HbA1c) values (National Glycohemoglobin Standardization Program : NGSP) ≤10.5% estimated glomerular filtration rate(eGFR) of ≥30 mL/min/1.73 m2 The median UACR of the first morning void urine samples is ≥50 mg/g Cr and &lt;300 mg/g Cr Stable blood pressure(diastolic blood pressure (DBP) &lt;100 mmHg and stable systolic blood pressure (SBP) &lt;160 mmHg) Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes. A diagnosis of nondiabetic renal disease. A following serum potassium level. eGFR of 3059mL/min/1.73m2; serum potassium level of &lt;3.5 or &gt;4.7 mmol/L, eGFR of ≥60mL/min/1.73m2: serum potassium level of &lt;3.5 or &gt;5.0 mmol/L symptomatic and clinically significant hypotension(diastolic blood pressure(DBP)&lt;50mmHg and systolic blood pressure(SBP)&lt;110mmHg) QT prolongation or torsades de pointes, or, a history or family history of QT prolongation or torsades de pointes New York Heart Association (NYHA) Class III or IV heart failure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>